B
United Therapeutics Corporation
UTHR
$322.94
$15.705.11%
B
Buy
2/27/2025Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 2/27/2025 due to a decline in the growth index, total return index and solvency index. EBIT declined 11.34% from $408.2M to $361.9M, operating cash flow declined 9.54% from $377.2M to $341.2M, and earnings per share declined from $6.39 to $6.1845.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 2/27/2025 due to a decline in the growth index, total return index and solvency index. EBIT declined 11.34% from $408.2M to $361.9M, operating cash flow declined 9.54% from $377.2M to $341.2M, and earnings per share declined from $6.39 to $6.1845.
B
Buy
2/21/2025Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 2/21/2025 due to an increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 2/21/2025 due to an increase in the total return index and volatility index.
B
Buy
2/6/2025Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 2/6/2025 due to a noticeable decline in the valuation index, growth index and total return index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 2/6/2025 due to a noticeable decline in the valuation index, growth index and total return index.
B
Buy
5/14/2024Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 5/14/2024 due to a major increase in the growth index, total return index and efficiency index. Operating cash flow increased 149.83% from $150.7M to $376.5M, earnings per share increased from $4.3524 to $6.17, and net income increased 41.23% from $217.1M to $306.6M.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 5/14/2024 due to a major increase in the growth index, total return index and efficiency index. Operating cash flow increased 149.83% from $150.7M to $376.5M, earnings per share increased from $4.3524 to $6.17, and net income increased 41.23% from $217.1M to $306.6M.
B
Buy
4/17/2024Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/17/2024 due to an increase in the volatility index, total return index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/17/2024 due to an increase in the volatility index, total return index and valuation index.
C
Hold
3/27/2024Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 3/27/2024 due to a decline in the volatility index, total return index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 3/27/2024 due to a decline in the volatility index, total return index and valuation index.
B
Buy
3/12/2024Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 3/12/2024 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 3.16% from $6.51B to $6.72B.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 3/12/2024 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 3.16% from $6.51B to $6.72B.
C
Hold
1/4/2024Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 1/4/2024 due to a decline in the total return index, volatility index and efficiency index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 1/4/2024 due to a decline in the total return index, volatility index and efficiency index.
B
Buy
5/12/2023Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 5/12/2023 due to a substantial decline in the total return index, volatility index and growth index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 5/12/2023 due to a substantial decline in the total return index, volatility index and growth index.
B
Buy
2/21/2023Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 2/21/2023 due to a large decline in the total return index.
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 2/21/2023 due to a large decline in the total return index.
B
Buy
12/23/2022Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 12/23/2022 due to a decline in the total return index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 12/23/2022 due to a decline in the total return index and valuation index.
A
Buy
12/8/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to A- from B+ on 12/8/2022 due to a noticeable increase in the total return index.
United Therapeutics Corporation (UTHR) was upgraded to A- from B+ on 12/8/2022 due to a noticeable increase in the total return index.
B
Buy
11/3/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 11/3/2022 due to a large increase in the total return index, growth index and valuation index. Earnings per share increased from $2.41 to $4.91, operating cash flow increased 103.62% from $127M to $258.6M, and EBIT increased 55.75% from $201.8M to $314.3M.
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 11/3/2022 due to a large increase in the total return index, growth index and valuation index. Earnings per share increased from $2.41 to $4.91, operating cash flow increased 103.62% from $127M to $258.6M, and EBIT increased 55.75% from $201.8M to $314.3M.
B
Buy
9/21/2022Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 9/21/2022 due to a significant decline in the total return index.
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 9/21/2022 due to a significant decline in the total return index.
B
Buy
9/6/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 9/6/2022 due to a large increase in the total return index, volatility index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 9/6/2022 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
8/4/2022Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 8/4/2022 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 56.01% from $288.7M to $127M, earnings per share declined from $5.03 to $2.41, and EBIT declined 29.93% from $288M to $201.8M.
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 8/4/2022 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 56.01% from $288.7M to $127M, earnings per share declined from $5.03 to $2.41, and EBIT declined 29.93% from $288M to $201.8M.
B
Buy
6/28/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 6/28/2022 due to a significant increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 6/28/2022 due to a significant increase in the total return index and volatility index.
B
Buy
6/15/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 6/15/2022 due to an increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 6/15/2022 due to an increase in the total return index and volatility index.
B
Buy
5/4/2022Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 5/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $2.3478 to $5.03, net income increased 113.81% from $112.2M to $239.9M, and EBIT increased 70.21% from $169.2M to $288M.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 5/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $2.3478 to $5.03, net income increased 113.81% from $112.2M to $239.9M, and EBIT increased 70.21% from $169.2M to $288M.
C
Hold
2/28/2022Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 2/28/2022 due to a decline in the total return index, growth index and solvency index. Earnings per share declined from $3.42 to $2.3478, EBIT declined 26.02% from $228.7M to $169.2M, and total revenue declined 6.63% from $444.7M to $415.2M.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 2/28/2022 due to a decline in the total return index, growth index and solvency index. Earnings per share declined from $3.42 to $2.3478, EBIT declined 26.02% from $228.7M to $169.2M, and total revenue declined 6.63% from $444.7M to $415.2M.
B
Buy
12/22/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 12/22/2021 due to an increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 12/22/2021 due to an increase in the total return index and volatility index.
C
Hold
12/3/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 12/3/2021 due to a significant decline in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 12/3/2021 due to a significant decline in the total return index and volatility index.
B
Buy
11/30/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 11/30/2021 due to a noticeable decline in the total return index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 11/30/2021 due to a noticeable decline in the total return index.
B
Buy
11/15/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from C+ on 11/15/2021 due to a significant increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B from C+ on 11/15/2021 due to a significant increase in the total return index and volatility index.
C
Hold
11/4/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 11/4/2021 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $3.65 to $3.42, and total revenue declined 0.4% from $446.5M to $444.7M.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 11/4/2021 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $3.65 to $3.42, and total revenue declined 0.4% from $446.5M to $444.7M.
B
Buy
9/24/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 9/24/2021 due to a decline in the total return index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 9/24/2021 due to a decline in the total return index.
B
Buy
9/9/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 9/9/2021 due to an increase in the total return index.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 9/9/2021 due to an increase in the total return index.
B
Buy
8/25/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 8/25/2021 due to a decline in the total return index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 8/25/2021 due to a decline in the total return index and valuation index.
B
Buy
8/10/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 8/10/2021 due to a noticeable increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 8/10/2021 due to a noticeable increase in the total return index and volatility index.
B
Buy
8/5/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 8/5/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.61 to $3.65, EBIT increased 238.72% from $65.6M to $222.2M, and operating cash flow increased 65.03% from $89.8M to $148.2M.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 8/5/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.61 to $3.65, EBIT increased 238.72% from $65.6M to $222.2M, and operating cash flow increased 65.03% from $89.8M to $148.2M.
C
Hold
5/7/2021Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 5/7/2021 due to a noticeable decline in the growth index, valuation index and efficiency index. Earnings per share declined from $2.1875 to $0.61, net income declined 71.36% from $98.8M to $28.3M, and operating cash flow declined 28.84% from $126.2M to $89.8M.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 5/7/2021 due to a noticeable decline in the growth index, valuation index and efficiency index. Earnings per share declined from $2.1875 to $0.61, net income declined 71.36% from $98.8M to $28.3M, and operating cash flow declined 28.84% from $126.2M to $89.8M.
B
Buy
4/19/2021Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/19/2021 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 2.75% from $4.08B to $4.2B.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/19/2021 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 2.75% from $4.08B to $4.2B.
C
Hold
11/27/2020Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 11/27/2020 due to an increase in the growth index and volatility index. Earnings per share increased from $2.41 to $3.84, EBIT increased 57.37% from $140.5M to $221.1M, and operating cash flow increased 52.99% from $164M to $250.9M.
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 11/27/2020 due to an increase in the growth index and volatility index. Earnings per share increased from $2.41 to $3.84, EBIT increased 57.37% from $140.5M to $221.1M, and operating cash flow increased 52.99% from $164M to $250.9M.
C
Hold
8/14/2020Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 8/14/2020 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 23.58% from $214.6M to $164M, earnings per share declined from $3.12 to $2.41, and EBIT declined 15.72% from $166.7M to $140.5M.
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 8/14/2020 due to a large decline in the growth index, valuation index and volatility index. Operating cash flow declined 23.58% from $214.6M to $164M, earnings per share declined from $3.12 to $2.41, and EBIT declined 15.72% from $166.7M to $140.5M.
C
Hold
6/26/2020Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 6/26/2020 due to a major increase in the growth index, total return index and solvency index.
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 6/26/2020 due to a major increase in the growth index, total return index and solvency index.
C
Hold
4/30/2020Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C from D+ on 4/30/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 161.79% from $52.6M to $137.7M, earnings per share increased from $1.1945 to $3.12, and EBIT increased 157.65% from $64.7M to $166.7M.
United Therapeutics Corporation (UTHR) was upgraded to C from D+ on 4/30/2020 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 161.79% from $52.6M to $137.7M, earnings per share increased from $1.1945 to $3.12, and EBIT increased 157.65% from $64.7M to $166.7M.
D
Sell
3/31/2020Upgraded
United Therapeutics Corporation (UTHR) was upgraded to D+ from D on 3/31/2020 due to an increase in the volatility index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to D+ from D on 3/31/2020 due to an increase in the volatility index and valuation index.
D
Sell
3/16/2020Downgrade
United Therapeutics Corporation (UTHR) was downgraded to D from D+ on 3/16/2020 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 64.72% from $183.4M to $64.7M, earnings per share declined from $3.01 to $1.1945, and net income declined 60.27% from $132.4M to $52.6M.
United Therapeutics Corporation (UTHR) was downgraded to D from D+ on 3/16/2020 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 64.72% from $183.4M to $64.7M, earnings per share declined from $3.01 to $1.1945, and net income declined 60.27% from $132.4M to $52.6M.
D
Sell
1/28/2020Upgraded
United Therapeutics Corporation (UTHR) was upgraded to D+ from D on 1/28/2020 due to a noticeable increase in the solvency index, growth index and volatility index. Operating cash flow increased 39.5% from $132.9M to $185.4M, debt to equity declined from 0.41 to 0.37, and total revenue increased 7.47% from $373.6M to $401.5M.
United Therapeutics Corporation (UTHR) was upgraded to D+ from D on 1/28/2020 due to a noticeable increase in the solvency index, growth index and volatility index. Operating cash flow increased 39.5% from $132.9M to $185.4M, debt to equity declined from 0.41 to 0.37, and total revenue increased 7.47% from $373.6M to $401.5M.
D
Sell
5/7/2019Downgrade
United Therapeutics Corporation (UTHR) was downgraded to D from C on 5/7/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.48 to -$11.32, net income declined 857.43% from $65.3M to -$494.6M, and operating cash flow declined 629.9% from $118.4M to -$627.4M.
United Therapeutics Corporation (UTHR) was downgraded to D from C on 5/7/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.48 to -$11.32, net income declined 857.43% from $65.3M to -$494.6M, and operating cash flow declined 629.9% from $118.4M to -$627.4M.
C
Hold
12/26/2018Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C from C- on 12/26/2018 due to an increase in the volatility index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to C from C- on 12/26/2018 due to an increase in the volatility index and valuation index.
C
Hold
12/7/2018Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C- from C on 12/7/2018 due to a major decline in the growth index, total return index and valuation index. Earnings per share declined from $3.98 to $2.42, EBIT declined 30.04% from $217.4M to $152.1M, and total revenue declined 7.15% from $444.5M to $412.7M.
United Therapeutics Corporation (UTHR) was downgraded to C- from C on 12/7/2018 due to a major decline in the growth index, total return index and valuation index. Earnings per share declined from $3.98 to $2.42, EBIT declined 30.04% from $217.4M to $152.1M, and total revenue declined 7.15% from $444.5M to $412.7M.
C
Hold
8/14/2018Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C from C- on 8/14/2018 due to a major increase in the growth index, valuation index and total return index. Total revenue increased 14.21% from $389.2M to $444.5M.
United Therapeutics Corporation (UTHR) was upgraded to C from C- on 8/14/2018 due to a major increase in the growth index, valuation index and total return index. Total revenue increased 14.21% from $389.2M to $444.5M.
C
Hold
4/20/2018Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C- from C on 4/20/2018 due to a large decline in the total return index, volatility index and growth index. Operating cash flow declined 133.19% from $258.5M to -$85.8M, earnings per share declined from $6.27 to $0.4316, and EBIT declined 57.07% from $323.8M to $139M.
United Therapeutics Corporation (UTHR) was downgraded to C- from C on 4/20/2018 due to a large decline in the total return index, volatility index and growth index. Operating cash flow declined 133.19% from $258.5M to -$85.8M, earnings per share declined from $6.27 to $0.4316, and EBIT declined 57.07% from $323.8M to $139M.
C
Hold
7/28/2017Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 7/28/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $3.89 to -$1.25, operating cash flow declined 69.37% from $230.8M to $70.7M, and the quick ratio declined from 3.14 to 1.66.
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 7/28/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $3.89 to -$1.25, operating cash flow declined 69.37% from $230.8M to $70.7M, and the quick ratio declined from 3.14 to 1.66.
C
Hold
7/19/2017Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 7/19/2017 due to an increase in the total return index, volatility index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 7/19/2017 due to an increase in the total return index, volatility index and valuation index.
C
Hold
6/27/2017Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 6/27/2017 due to a decline in the volatility index, total return index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 6/27/2017 due to a decline in the volatility index, total return index and valuation index.
C
Hold
5/1/2017Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 5/1/2017 due to a decline in the total return index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 5/1/2017 due to a decline in the total return index and valuation index.
B
Buy
4/24/2017Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/24/2017 due to an increase in the total return index, valuation index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 4/24/2017 due to an increase in the total return index, valuation index and volatility index.
C
Hold
4/6/2017Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 4/6/2017 due to a decline in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B- on 4/6/2017 due to a decline in the total return index and volatility index.
B
Buy
3/22/2017Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 3/22/2017 due to a noticeable increase in the total return index, growth index and efficiency index. Total capital increased 0.69% from $1.84B to $1.85B, and total revenue increased 0.2% from $408.2M to $409M.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 3/22/2017 due to a noticeable increase in the total return index, growth index and efficiency index. Total capital increased 0.69% from $1.84B to $1.85B, and total revenue increased 0.2% from $408.2M to $409M.
C
Hold
3/11/2016Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from B+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
United Therapeutics Corporation (UTHR) was downgraded to C+ from B+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
B
Buy
2/26/2016Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 2/26/2016 due to a substantial decline in the growth index and volatility index. Operating cash flow declined 87.69% from $207.31M to $25.52M, earnings per share declined from $9.24 to $2.0984, and EBIT declined 59.94% from $387.08M to $155.06M.
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 2/26/2016 due to a substantial decline in the growth index and volatility index. Operating cash flow declined 87.69% from $207.31M to $25.52M, earnings per share declined from $9.24 to $2.0984, and EBIT declined 59.94% from $387.08M to $155.06M.
A
Buy
10/28/2015Upgraded
United Therapeutics Corporation (UTHR) was upgraded to A- from B- on 10/28/2015 due to a significant increase in the valuation index, growth index and solvency index. Operating cash flow increased 405.86% from $40.98M to $207.31M, earnings per share increased from $1.91 to $9.24, and EBIT increased 125.43% from $171.71M to $387.08M.
United Therapeutics Corporation (UTHR) was upgraded to A- from B- on 10/28/2015 due to a significant increase in the valuation index, growth index and solvency index. Operating cash flow increased 405.86% from $40.98M to $207.31M, earnings per share increased from $1.91 to $9.24, and EBIT increased 125.43% from $171.71M to $387.08M.
B
Buy
10/9/2015Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 10/9/2015 due to a large increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.11 to 0.03, and total revenue increased 6% from $327.5M to $347.16M.
United Therapeutics Corporation (UTHR) was upgraded to B- from C+ on 10/9/2015 due to a large increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.11 to 0.03, and total revenue increased 6% from $327.5M to $347.16M.
C
Hold
6/29/2015Upgraded
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 6/29/2015 due to an increase in the valuation index.
United Therapeutics Corporation (UTHR) was upgraded to C+ from C on 6/29/2015 due to an increase in the valuation index.
C
Hold
6/3/2015Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 6/3/2015 due to a decline in the valuation index, solvency index and total return index.
United Therapeutics Corporation (UTHR) was downgraded to C from C+ on 6/3/2015 due to a decline in the valuation index, solvency index and total return index.
C
Hold
4/30/2015Downgrade
United Therapeutics Corporation (UTHR) was downgraded to C+ from A- on 4/30/2015 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $2.1687 to -$0.36, EBIT declined 108.3% from $178.58M to -$14.83M, and total revenue declined 5.44% from $346.36M to $327.5M.
United Therapeutics Corporation (UTHR) was downgraded to C+ from A- on 4/30/2015 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $2.1687 to -$0.36, EBIT declined 108.3% from $178.58M to -$14.83M, and total revenue declined 5.44% from $346.36M to $327.5M.
A
Buy
2/25/2015Upgraded
United Therapeutics Corporation (UTHR) was upgraded to A- from B- on 2/25/2015 due to a major increase in the valuation index, growth index and total return index. Total revenue increased 4.97% from $329.95M to $346.36M.
United Therapeutics Corporation (UTHR) was upgraded to A- from B- on 2/25/2015 due to a major increase in the valuation index, growth index and total return index. Total revenue increased 4.97% from $329.95M to $346.36M.
B
Buy
1/5/2015Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 1/5/2015 due to a noticeable decline in the total return index, solvency index and valuation index.
United Therapeutics Corporation (UTHR) was downgraded to B- from B on 1/5/2015 due to a noticeable decline in the total return index, solvency index and valuation index.
B
Buy
11/19/2014Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 11/19/2014 due to a large increase in the total return index, volatility index and valuation index.
United Therapeutics Corporation (UTHR) was upgraded to B from B- on 11/19/2014 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
10/29/2014Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B- from B+ on 10/29/2014 due to a large decline in the valuation index, growth index and efficiency index. Operating cash flow declined 482.78% from -$54.48M to $208.54M, earnings per share declined from $2.1 to -$0.5336, and net income declined 122.56% from $111.85M to -$25.24M.
United Therapeutics Corporation (UTHR) was downgraded to B- from B+ on 10/29/2014 due to a large decline in the valuation index, growth index and efficiency index. Operating cash flow declined 482.78% from -$54.48M to $208.54M, earnings per share declined from $2.1 to -$0.5336, and net income declined 122.56% from $111.85M to -$25.24M.
B
Buy
10/1/2014Upgraded
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 10/1/2014 due to a noticeable increase in the total return index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to B+ from B on 10/1/2014 due to a noticeable increase in the total return index and volatility index.
B
Buy
9/16/2014Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 9/16/2014 due to a decline in the valuation index.
United Therapeutics Corporation (UTHR) was downgraded to B from B+ on 9/16/2014 due to a decline in the valuation index.
B
Buy
7/30/2014Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 7/30/2014 due to a substantial decline in the growth index and solvency index. Operating cash flow declined 149.26% from $110.6M to -$54.48M, debt to equity increased from 0.22 to 0.45, and EBIT declined 18.42% from $216.14M to $176.32M.
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 7/30/2014 due to a substantial decline in the growth index and solvency index. Operating cash flow declined 149.26% from $110.6M to -$54.48M, debt to equity increased from 0.22 to 0.45, and EBIT declined 18.42% from $216.14M to $176.32M.
A
Buy
6/3/2014Upgraded
United Therapeutics Corporation (UTHR) was upgraded to A- from B+ on 6/3/2014 due to an increase in the valuation index and volatility index.
United Therapeutics Corporation (UTHR) was upgraded to A- from B+ on 6/3/2014 due to an increase in the valuation index and volatility index.
B
Buy
5/19/2014Downgrade
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 5/19/2014 due to a decline in the valuation index.
United Therapeutics Corporation (UTHR) was downgraded to B+ from A- on 5/19/2014 due to a decline in the valuation index.
A
Buy
5/2/2014Upgraded
United Therapeutics Corporation (UTHR) was upgraded to A- from B on 5/2/2014 due to a significant increase in the growth index, valuation index and solvency index. The quick ratio increased from 1.18 to 1.35, operating cash flow increased 5.91% from $104.42M to $110.6M, and debt to equity declined from 0.23 to 0.22.
United Therapeutics Corporation (UTHR) was upgraded to A- from B on 5/2/2014 due to a significant increase in the growth index, valuation index and solvency index. The quick ratio increased from 1.18 to 1.35, operating cash flow increased 5.91% from $104.42M to $110.6M, and debt to equity declined from 0.23 to 0.22.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
